Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:28:07 ON 17 FEB 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:28:24 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5
DICTIONARY FILE UPDATES: 15 FEB 2006 HIGHEST RN 874326-73-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10500516.str

chain nodes :
9 10
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
8-9 9-10
ring bonds :
1-2 1-5 1-6 2-3 3-4 3-7 4-5 6-8 7-8
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 3-7 4-5 6-8 7-8 8-9 9-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:29:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1756 TO ITERATE

100.0% PROCESSED 1756 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 32607 TO 37633
PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:29:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 35998 TO ITERATE

100.0% PROCESSED 35998 ITERATIONS 181 ANSWERS
SEARCH TIME: 00.00.01

L3 181 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.38 167.59

FILE 'CAPLUS' ENTERED AT 10:29:25 ON 17 FEB 2006

FILE COVERS 1907 - 17 Feb 2006 VOL 144 ISS 9
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 22 L3

=> d ibib abs hitstr 1-22

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1103769 CAPLUS
DOCUMENT NUMBER: 143:386926
TITLE: Preparation of N-(2-pyridyl)cyclic amine derivatives as pest control agents
INVENTOR(S): Hamamoto, Isami; Takahashi, Jun; Yano, Makio; Hanai, Daisuke; Iwasa, Takao
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095380	A1	20051013	WO 2005-JP6887	20050330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2004-106668 A 20040331
JP 2004-374007 A 20041224
OTHER SOURCE(S): MARPAT 143:386926
GI



I

AB The title compds. (I) [R1 = HO, halo, cyano, NO2, CHO, each (un)substituted C1-6 alkyl, C1-6 alkoxy, NH2, or 5- or 6-membered heterocyclyl containing at least one heteroatom selected from O, N, and S, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkenyl, C1-6 alkylcarbonyl, C1-6 haloalkoxy, C2-6 alkenyloxy, C2-6 haloalkenyloxy, C2-6 alkynyloxy, C1-6 alkylcarbonyloxy, C1-6 alkoxycarbonyloxy, C1-6 alkylthiocarbonyloxy, C1-6 alkylthio, C1-6 haloalkylthio, C1-6 alkylsulfinyl, C1-6 haloalkylsulfinyl, C1-6 alkylsulfonyl, etc.; m = 0-5; R2 = halo, NO2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, (un)substituted 5- or 6-membered heterocyclyl containing at least one heteroatom selected from O, N, and S; k = 0-4; R3, R31 R4, R41, R5, R51, R6, R61, R7 = H, C1-6 alkyl, C1-6 alkoxycarbonyl, C1-6 alkoxy; or R3 and R4 or R5 and R6 together form a saturated ring; X = O, S, S(O), S(O)2;n = 0, 1], salts, or N-oxide thereof are prepared Thus, a solution of 3.0 g 4-hydroxypiperidine and 5.4 g 2-chloro-5-trifluoromethylpyridine in 25 mL ethanol was treated with 4.5 g Et3N and refluxed overnight to give 5.98 g 1-[5-(Trifluoromethyl)pyridin-2-yl]piperidin-4-ol (II). A solution of II 4.9, 5-hydroxy-2-nitrobenzotrifluoride 3.2, and Ph3P 5.6 g in 30 mL THF was treated dropwise with a solution of 4.3 g diisopropyl azodicarboxylate in 30 mL THF under ice-cooling, warmed to room temperature, and stirred for 3 h to give 5.98 g 4-[4-Nitro-3-(trifluoromethyl)phenoxy]-1-[5-(trifluoromethyl)-2-pyridyl]-piperidine (III). A solution of 5.7 g III in 300 mL ethanol was treated with 18.8 g zinc powder and 1.9 g CaCl2.2H2O and refluxed overnight to give 5.4 g 4-[4-Amino-3-(trifluoromethyl)phenoxy]-1-[5-(trifluoromethyl)-2-pyridyl]-piperidine (IV). IV at 125 ppm controlled 100% adult Tetranychus urticae on kidney bean leaf.

IT **866615-54-5P 866778-29-2P**
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(2-pyridyl)cyclic amine derivs. as pesticides such as insecticides and miticides)

RN 866615-54-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[2-propoxy-4-(trifluoromethyl)phenyl]thio]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866778-29-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[2-propoxy-4-(trifluoromethyl)phenyl]thio]-8-[5-(trifluoromethyl)-2-pyridinyl]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1154707 CAPLUS
DOCUMENT NUMBER: 142:94018
TITLE: Preparation of novel 8-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as monoamine neurotransmitter re-uptake inhibitors
INVENTOR(S): Peters, Dan; Eriksen, Birgitte L.; Nielsen, Elsebet Ostergaard; Scheel-Krueger, Jorgen; Olsen, Gunnar M.
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113334	A1	20041229	WO 2004-EP51167	20040618

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
DK 2003-939	A	20030624
US 2003-482566P	P	20030626
DK 2003-1487	A	20031009
US 2003-509808P	P	20031010
DK 2004-228	A	20040213
US 2004-544210P	P	20040213

OTHER SOURCE(S): MARPAT 142:94018
GI



AB 8-Azabicyclo[3.2.1]octane derivs. of tropine and pseudotropine, such as I [R = H, alkyl; R1 = aryl, heteroaryl; X = O, S, NR3; R3 = H, alkyl, acyl, sulfonyl, etc.], were prepared for therapeutic use in the treatment of diseases, disorders or conditions responsive to inhibition of monoamine neurotransmitter reuptake in the central nervous system (CNS). The CNS disorders claimed for treatment include mood disorder, depression, atypical depression, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, posttraumatic stress disorder, acute stress disorder, drug addiction, drug misuse, cocaine abuse, nicotine abuse, tobacco abuse and alcoholism. Further, the CNS disorders claimed for treatment include pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, postoperative pain, post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, posttraumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourette's disease. Thus, endo-8-azabicyclo[3.2.1]octane derivative II was prepared in 33% yield by reacting tropine with tetrahydrothiophene using t-BuOK and 18-crown-6 ether in DMF. Dosages and pharmaceutical compns. of these 8-azabicyclo[3.2.1]octanes were discussed.

IT **817194-81-3P**, exo-3-(3,4-Dichlorophenylthio)-8-methyl-8-azabicyclo[3.2.1]octane **817194-82-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 8-azabicyclo[3.2.1]octane tropine or pseudotropine derivs. for use in pharmaceutical compns. as monoamine neurotransmitter re-uptake inhibitors)

RN 817194-81-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(3,4-dichlorophenyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 817194-82-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3,4-dichlorophenyl)thio]-8-methyl-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-81-3
CMF C14 H17 Cl2 N S

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:696386 CAPLUS
DOCUMENT NUMBER: 141:225725
TITLE: Preparation of antiparasitic terpene alkaloids
INVENTOR(S): Chubb, Nathan Anthony Logan; Critcher, Douglas James; Eshelby, James John; Lunn, Graham; Rudge, Andrew John; Walshe, Nigel Derek; Wiedenau, Paul Heinrich; Williams, David Howard
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072086	A2	20040826	WO 2004-IB320	20040203
WO 2004072086	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515343	AA	20040826	CA 2004-2515343	20040203
EP 1597264	A2	20051123	EP 2004-707603	20040203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 2005003313	A	20050808	NO 2005-3313	20050706
PRIORITY APPLN. INFO.:			GB 2003-3439 A	20030214
			US 2003-303439 A	20030214
			WO 2004-IB320 W	20040203

OTHER SOURCE(S): MARPAT 141:225725

GI



I

AB The present invention relates to novel terpene alkaloids, such as I [R1 = alkyl, haloalkyl, cycloalkyl, alkynyl, aryl, alkoxy, etc.; R2 = alkyl, alkenyl, aminoalkyl, carboxamidoalkyl, alkoxyalkyl, acyloxyalkyl, etc.], and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivs. of the terpene alkaloid (1S,2R,4aR,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate I [R1 = COMe, R2 = C(Me):CH2]. Pharmaceutical compns. comprising the same are also disclosed.

IT **746653-54-3P 746653-58-7P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of terpene alkaloids for use in antiparasitic pharmaceutical compns.)

RN 746653-54-3 CAPLUS

CN Pyrrolo[2,3-c][2,1]benzoxazine-2-carboxylic acid, 6-chloro-1,2,3,3a,5,9b-hexahydro-9b-hydroxy-5-methyl-, (1S,2R,4aS,5S,8R,8aR)-2-(acetyloxy)-

1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-5-[2-[3-[(4-methoxyphenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-methylethyl]-3,8-dimethyl-1-naphthalenyl ester, (2S,3aR,9bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746653-58-7 CAPLUS

CN Pyrrolo[2,3-c][2,1]benzoxazine-2-carboxylic acid, 6-chloro-1,2,3,3a,5,9b-hexahydro-9b-hydroxy-5-methyl-, (1S,2R,4aS,5S,8R,8aR)-2-(acetyloxy)-5-[2-[3-[(4-fluorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-methylethyl]-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3,8-dimethyl-1-naphthalenyl ester, (2S,3aR,9bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **745066-21-1P 745066-22-2P 745066-23-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of terpene alkaloids for use in antiparasitic pharmaceutical compns.)

RN 745066-21-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(4-methoxyphenyl)thio]- (9CI) (CA INDEX NAME)

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1472248 A1 20041103 EP 2002-756388 20020729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
US 2005182088 A1 20050818 US 2003-500516 20020729
PRIORITY APPLN. INFO.: US 2002-350152P P 20020117
WO 2002-US21296 W 20020729
OTHER SOURCE(S): MARPAT 139:149805
GI



I



II

AB Arylthio substituted azabicyclic compds., such as I [R = R1 = H; RR1 = bond; R2 = aryl, heteroaryl; X = S, SO2], were prepared for therapeutic uses that require modulation of neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine and are useful for the treatment of disorders of the central and autonomic nervous systems. More particularly, the present invention relates to thio-bridged aryl compds. that are capable of modulating acetylcholine receptors and pharmaceutical compns. comprising such compds. Thus, exo-3-(3-methoxyphenylthio)-8-methyl-8-azabicyclo[3.2.1]octane (II) was prepared with 41% yield by a stereoselective substitution reaction of 3-methoxybenzenethiol with endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl methanesulfonate using NaH in THF. Effects of the prepared azabicyclics on nicotine receptor β4 subtypes were determined using a functional Ca-flux assay.

IT **569339-16-8P 569339-18-0P 569339-27-1P**
569339-29-3P 569339-31-7P 569339-57-7P
569339-58-8P 569339-60-2P 569339-61-3P
569339-62-4P 569339-75-9P 569339-76-0P
569339-82-8P 569339-83-9P 569339-95-3P
569339-96-4P 569339-97-5P 569339-98-6P
569340-01-8P 569340-02-9P 569340-03-0P
569340-13-2P 569340-14-3P 569340-15-4P
569340-16-5P 569340-25-6P 569340-26-7P
569340-30-3P 569340-32-5P 569340-33-6P
569340-40-5P 569340-41-6P 569340-42-7P
569340-43-8P 569340-44-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylthio-azabicyclic derivs. for use in pharmaceutical compns. as modulators of acetylcholine receptors)

RN 569339-16-8 CAPLUS

CN Benzenamine, 4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-18-0 CAPLUS
CN Benzenamine, 3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-27-1 CAPLUS
CN Benzamide, N-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-29-3 CAPLUS
CN Benzoic acid, 3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-31-7 CAPLUS
CN Phenol, 3-bromo-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-57-7 CAPLUS
CN 2-Pyridinamine, 5-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-58-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-[(6-nitro-3-pyridinyl)thio]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-60-2 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-61-3 CAPLUS
CN Phenol, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-62-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2-chloro-4-(3-pyridinyl)phenyl]thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-75-9 CAPLUS
CN Acetonitrile, [3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-76-0 CAPLUS
CN Acetic acid, [3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenoxy]difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-82-8 CAPLUS
CN 2-Propenoic acid, 3-[3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 569339-83-9 CAPLUS
CN 2-Propenoic acid, 3-[3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 569339-95-3 CAPLUS
CN Benzoic acid, 2-chloro-3-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-6-nitro-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-96-4 CAPLUS
CN Benzoic acid, 6-amino-2-chloro-3-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-97-5 CAPLUS
CN Benzenemethanol, 6-amino-2-chloro-3-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-98-6 CAPLUS
CN 2H-3,1-Benzoxazin-2-one, 5-chloro-1,4-dihydro-6-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 569339-94-2
CMF C16 H19 Cl N2 O2 S

Relative stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 569340-01-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-[(5-nitro-1-oxido-6-quinolinyl)thio]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-02-9 CAPLUS
CN 5-Quinolinamine, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, 1-oxide (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-03-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-1-oxido-6-quinolinyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-13-2 CAPLUS
CN Benzenamine, 2-chloro-N-methyl-3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-6-nitro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-14-3 CAPLUS
CN 1,2-Benzenediamine, 3-chloro-N2-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-15-4 CAPLUS
CN 1,2-Benzenediamine, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-N2-propyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-16-5 CAPLUS
CN 1,2-Benzenediamine, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-N2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-25-6 CAPLUS
CN Phenol, 2-chloro-3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-6-nitro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-26-7 CAPLUS
CN Phenol, 6-amino-2-chloro-3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-30-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-1H-indazol-5-yl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-32-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2-chloro-3-methyl-4-nitrophenyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-33-6 CAPLUS
CN Benzenamine, 3-chloro-2-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-40-5 CAPLUS

CN 2(1H)-Quinolinone, 5,7-dichloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-41-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2,6-dichloro-4-nitrophenyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-42-7 CAPLUS
CN Benzenamine, 3,5-dichloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-43-8 CAPLUS
CN 2-Propenamide, N-[3,5-dichloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]-3-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 569340-44-9 CAPLUS

CN 2-Propenamide, N-[3,5-dichloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]-3-ethoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



● HCl

IT **569339-67-9 569339-70-4**
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of arylthio-azabicyclic derivs. for use in pharmaceutical compns. as modulators of acetylcholine receptors)

RN 569339-67-9 CAPLUS
CN Benzenamine, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-70-4 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **16487-41-5P 569339-10-2P**, exo-3-(3-Methoxyphenylthio)-8-methyl-8-azabicyclo[3.2.1]octane **569339-11-3P**
569339-12-4P 569339-14-6P 569339-20-4P
569339-22-6P 569339-24-8P 569339-26-0P
569339-30-6P 569339-32-8P 569339-38-4P
569339-40-8P 569339-41-9P 569339-43-1P
569339-47-5P 569339-51-1P 569339-52-2P

569339-63-5P 569339-65-7P 569339-66-8P
569339-68-0P 569339-69-1P 569339-71-5P
569339-72-6P 569339-74-8P 569339-78-2P
569339-79-3P 569339-81-7P 569339-84-0P
569339-85-1P 569339-87-3P 569339-88-4P
569339-94-2P 569339-99-7P 569340-04-1P
569340-05-2P 569340-10-9P 569340-11-0P
569340-12-1P 569340-17-6P 569340-18-7P
569340-19-8P 569340-20-1P 569340-21-2P
569340-23-4P 569340-27-8P 569340-28-9P
569340-34-7P 569340-35-8P 569340-36-9P
569340-37-0P 569340-38-1P 569340-39-2P
569340-45-0P 569340-46-1P 569340-47-2P
569340-48-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylthio-azabicyclic derivs. for use in pharmaceutical compns. as modulators of acetylcholine receptors)

RN 16487-41-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-10-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3-methoxyphenyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-11-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-methoxyphenyl)thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-12-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2-chlorophenyl)thio]-8-methyl-, (3-exo)-

(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-14-6 CAPLUS
CN Benzamide, 3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-20-4 CAPLUS
CN Methanesulfonamide, N-[4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-22-6 CAPLUS
CN Acetamide, N-[4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-24-8 CAPLUS
CN Acetamide, N-[3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-26-0 CAPLUS
CN Benzamide, 4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-30-6 CAPLUS
CN Benzenemethanol, 3-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-32-8 CAPLUS
CN Benzonitrile, 5-hydroxy-2-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-38-4 CAPLUS
CN Phenol, 2-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 569339-37-3
CMF C15 H21 N O S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 569339-40-8 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 5-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 569339-39-5
CMF C20 H23 N O S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 569339-41-9 CAPLUS
CN Phenol, 2,5-dichloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-43-1 CAPLUS
CN Phenol, 2,6-dichloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-47-5 CAPLUS
CN Phenol, 2-bromo-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-51-1 CAPLUS
CN Phenol, 3-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-52-2 CAPLUS
CN Phenol, 3-methyl-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-,

trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 569339-51-1
CMF C15 H21 N O S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 569339-63-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-[[4-(5-pyrimidinyl)phenyl]thio]-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-65-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-([1,1'-biphenyl]-4-ylthio)-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-66-8 CAPLUS
CN Formamide, N-[3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-68-0 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-69-1 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-71-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2-chloro-4-(3-pyridinyloxy)phenyl]thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-72-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[2-chloro-4-(pyrazinyloxy)phenyl]thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-74-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2-chloro-4-(1H-1,2,4-triazol-3-ylmethoxy)phenyl]thio]-8-methyl-, (3-exo)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 569339-73-7
CMF C17 H21 Cl N4 O S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 569339-78-2 CAPLUS
CN Formic acid, compd. with 2-[3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenoxy]-N-ethylacetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 569339-77-1
CMF C18 H25 Cl N2 O2 S

Relative stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 569339-79-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2-chloro-4-(phenylmethoxy)phenyl]thio]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-81-7 CAPLUS
CN Benzenepropanoic acid, 3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 569339-80-6
CMF C17 H22 Cl N O2 S

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 569339-84-0 CAPLUS
CN 3-Pyridinamine, N-[3-chloro-4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-85-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1H-indazol-5-ylthio)-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-87-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1H-indol-5-ylthio)-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-88-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1H-benzotriazol-5-ylthio)-8-methyl-, (3-exo)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-94-2 CAPLUS
CN 2H-3,1-Benzoxazin-2-one, 5-chloro-1,4-dihydro-6-[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569339-99-7 CAPLUS
CN 2(1H)-Quinolinone, 5-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-04-1 CAPLUS
CN 2(1H)-Quinolinone, 5-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 569339-99-7
CMF C17 H19 Cl N2 O S

Relative stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 569340-05-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-10-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-11-0 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-12-1 CAPLUS
CN 2H-Benzimidazole-2-thione, 7-chloro-1,3-dihydro-1-methyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-17-6 CAPLUS
CN 2H-Benzimidazole-2-thione, 7-chloro-1,3-dihydro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-1-propyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-18-7 CAPLUS
CN 2H-Benzimidazole-2-thione, 7-chloro-1,3-dihydro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-19-8 CAPLUS
CN 2H-Benzimidazol-2-one, 7-chloro-1,3-dihydro-1-methyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-20-1 CAPLUS
CN 2H-Benzimidazol-2-one, 5-chloro-1,3-dihydro-1-methyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-21-2 CAPLUS
CN 2(3H)-Benzoxazolone, 5-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-23-4 CAPLUS
CN 2(3H)-Benzoxazolone, 7-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-27-8 CAPLUS
CN 2(3H)-Benzoxazolethione, 7-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-28-9 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 5-chloro-3-methyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-34-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-1H-indazol-5-yl)sulfonyl]-8-methyl-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-35-8 CAPLUS
CN 2(1H)-Quinolinone, 5,7-dichloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-36-9 CAPLUS
CN 2(3H)-Benzoxazolone, 5-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-37-0 CAPLUS
CN 2(1H)-Quinolinone, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-38-1 CAPLUS
CN 2(3H)-Benzoxazolone, 6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-39-2 CAPLUS
CN 2(3H)-Benzoxazolone, 7-chloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-45-0 CAPLUS
CN 2(1H)-Quinolinone, 5,7-dichloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 569340-46-1 CAPLUS
CN 2(1H)-Quinolinone, 5,7-dimethyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-47-2 CAPLUS
CN 2(1H)-Quinolinethione, 5,7-dichloro-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 569340-48-3 CAPLUS
CN 2(3H)-Benzoxazolone, 7-methyl-6-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **569339-64-6**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylthio-azabicyclic derivs. for use in pharmaceutical compns. as modulators of acetylcholine receptors)

RN 569339-64-6 CAPLUS

CN Methanesulfonic acid, trifluoro-, 4-[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]phenyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:817246 CAPLUS

DOCUMENT NUMBER: 135:357843

TITLE: Preparation of 2-Aryl indole derivatives for use as tachykinin receptor antagonists

INVENTOR(S): Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Ridgill, Mark Peter; Shaw, Duncan Edward

PATENT ASSIGNEE(S): UK

SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2001039286	A1	20011108	US 2001-782422		20010213
PRIORITY APPLN. INFO.:			GB 2000-3397	A	20000214

OTHER SOURCE(S): MARPAT 135:357843

GI



I

AB 2-Aryl indole derivs. I (wherein R1a, R1b, and R2 = a variety of substituents; R3 = optionally substituted Ph, biphenyl or naphthyl or heteroaryl group; R4 = H, (C1-6)alkyl, carbonyl (=O), (CH2)pphenyl or a (C1-2)alkylene bridge across the piperidine ring; R5 and R6 = variety of substituents; or R5 and R6 together are linked so as to form an optionally substituted 5-or 6-membered ring; X = O or S, two H atoms, boxHNH or

boxHN(C1-6 alkyl); Y = straight or branched (C1-4)alkylene, (C2-4)alkenylene or (C2-4)alkynylene chain; the dotted line represents an optional double bond; m = 0,1,2,3,4; n = 1,2,3,4; and p = 1,2,3,4), or a pharmaceutically acceptable salt thereof, were prepared, and their use as tachykinin receptor antagonists evaluated. Thus, diisopropylethylamine and bromoacetonitrile were added to a loaded resin (synthetic preparation given) in N-methylpyrrolidinone, to which was added a solution of 6-(methylsulfonyl)spiro-[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one in THF to give 1'-{3-[5-chloro-2-(4-chlorophenyl)-1H-indol-3-yl]-1-oxopropyl}-6-(methylsulfonyl)spiro(2H-1-benzopyran-2,4'-piperidin)-4(3H)-one. The compds. are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. Biol. data are given.

IT **371970-31-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl indole derivs. as tachykinin receptor antagonists for treatment for)

RN 371970-31-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-[5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indol-3-yl]propyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:792903 CAPLUS

DOCUMENT NUMBER: 134:147724

TITLE: BF3-Induced Rearrangement of Aziridino Cyclopropanes Derived from 2-Phenylsulfonyl 1,3-Dienes. Application to the Total Synthesis of (±)-Ferruginine

AUTHOR(S): Jonsson, Sandra Y.; Loefstroem, Claes M. G.; Baeckvall, Jan-E.

CORPORATE SOURCE: Department of Organic Chemistry Arrhenius Laboratory, Stockholm University, Stockholm, SE-106 91, Swed.

SOURCE: Journal of Organic Chemistry (2000), 65(25), 8454-8457
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:147724

GI



AB Total synthesis of the alkaloid (±)-ferruginine (I) has been developed via the 2-phenylsulfonyl 1,3-diene approach. BF3-induced rearrangement of the N-protected cyclohexane aziridino cyclopropane (II), derived from its corresponding epoxy cyclopropane, afforded the desired tropane alkaloid skeleton (III) in good yield. Michael addition of nitroethane (as an acyl anion equivalent) and transformation of the nitro group of the adduct (IV; X = NO2, dashed line = single bond) to a keto function gave (IV; X = O, dashed line = double bond). Elimination of benzenesulfinic acid and subsequent replacement of the tosyl group by a Me group afforded I.

IT **316129-46-1P 316129-47-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of ferruginine via BF3-induced rearrangement of aziridino cyclopropanes derived from 2-phenylsulfonyl 1,3-dienes)

RN 316129-46-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[(4-methylphenyl)sulfonyl]-2-(1-nitroethyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 316129-47-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 2-acetyl-8-[(4-methylphenyl)sulfonyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:378953 CAPLUS
DOCUMENT NUMBER: 133:193123
TITLE: Synthesis and analgesic activity of some side-chain modified anpirtoline derivatives
AUTHOR(S): Radl, Stanislav; Hezky, Petr; Proska, Jan; Hejnova, Lucie; Krejci, Ivan
CORPORATE SOURCE: Research Institute of Pharmacy and Biochemistry, Prague, 13060, Czech Rep.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2000), 333(5), 107-112
CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB New derivs. of anpirtoline and deazaanpirtoline modified in the side chain have been synthesized. The series includes compds. with side-chains containing piperidine or pyrrolidine rings, compds. containing 8-azabicyclo[3.2.1]octane moiety, and compds. having a piperazine ring in their side-chains. Their receptor binding profiles (5-HT1A, 5-HT1B) and analgesic activity (hot plate, acetic acid induced writhing) have been studied. Optimized structures (PM3-MOPAC, Alchemy 2000, Tripos Inc.) of the synthesized compds. were compared with that of anpirtoline.

IT **289677-88-9P 289677-89-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of some side-chain modified anpirtoline derivs.)

RN 289677-88-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro-2-pyridinyl)thio]-8-methyl-, monohydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 289677-89-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3-chlorophenyl)thio]-8-methyl-, hydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:505661 CAPLUS
DOCUMENT NUMBER: 131:157708
TITLE: Methods for controlling invertebrate pests using cocaine receptor binding ligands

INVENTOR(S): Kuhar, Michael J.; Carroll, Frank I.; Boja, John W.; Lewin, Anita H.; Abraham, Philip

PATENT ASSIGNEE(S): Research Triangle Institute, USA

SOURCE: U.S., 58 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5935953	A	19990810	US 1997-823563	19970325
US 564755	A0	19910801	US 1990-564755	19900809
US 5128118	A	19920707		
US 5413779	A	19950509	US 1993-972472	19930323
US 5736123	A	19980407	US 1995-436970	19950508
US 6531483	B1	20030311	US 1996-706263	19960904
CA 2263961	AA	19980226	CA 1997-2263961	19970822
WO 9807427	A1	19980226	WO 1997-US14702	19970822
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9742327	A1	19980306	AU 1997-42327	19970822
EP 993301	A1	20000419	EP 1997-940580	19970822
EP 993301	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001525795	T2	20011211	JP 1998-510955	19970822
AT 236635	E	20030415	AT 1997-940580	19970822
AU 2004200015	A1	20040129	AU 2004-200015	20040102

PRIORITY APPLN. INFO.:

US 1990-564755	A2	19900809
US 1993-972472	A2	19930323
US 1995-436970	A2	19950508
US 1995-506541	A2	19950724
US 1996-701503	A2	19960822
US 1996-706263	A2	19960904
WO 1991-US5553	W	19910809
US 1991-792648	B2	19911115
US 1993-164576	A2	19931210
US 1997-823563	A	19970325
WO 1997-US14702	W	19970822
AU 1999-40759	A3	19990520

OTHER SOURCE(S): MARPAT 131:157708

GI



I

AB Tropane derivs. such as I (R = heterocyclyl; X = Cl, Me) were prepared as inhibitors of a phenylethanolamine reuptake transporter in invertebrate pests. Thus, refluxing 2 mmol 3β-(4-chlorophenyl)tropane-2β-carboxylic acid in 2 mL POCl3 with 2.2 mmol benzoic acid hydrazide 2 h

gave a 42% yield of I (R = 5-phenyl-1,3,4-oxadiazol-2-yl, X = Cl). The IC50 values at dopamine, serotonin, and norepinephrine receptors were determined

IT **189264-14-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(controlling invertebrate pests by using cocaine receptor binding ligands)

RN 189264-14-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2R,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **189264-11-7P 189264-12-8P 189264-13-9P**
236753-74-5P 236753-75-6P 236753-76-7P
236753-77-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(controlling invertebrate pests by using cocaine receptor binding ligands)

RN 189264-11-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189264-12-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189264-13-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 236753-74-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3S,5S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189264-11-7
CMF C16 H21 N O2 S

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 236753-75-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2R,3S,5S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189264-12-8
CMF C16 H21 N O2 S

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 236753-76-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3R,5S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189264-13-9
CMF C16 H21 N O2 S

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 236753-77-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, hydrochloride, (1R,2R,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT **236753-79-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(controlling invertebrate pests by using cocaine receptor binding ligands)
RN 236753-79-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 3-(phenylthio)-, methyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:425750 CAPLUS
DOCUMENT NUMBER: 131:73564
TITLE: Preparation of pyridine compounds as acetylcholine receptor ligands
INVENTOR(S): Vernier, Jean-Michel; Cosford, Nicholas D. P.; Mc Donald, Ian A.
PATENT ASSIGNEE(S): Sibia Neurosciences, Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932117	A1	19990701	WO 1998-US27391	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6632823	B1	20031014	US 1997-996308	19971222
CA 2315941	AA	19990701	CA 1998-2315941	19981222
AU 9919437	A1	19990712	AU 1999-19437	19981222
EP 1043999	A1	20001018	EP 1998-964267	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001526226	T2	20011218	JP 2000-525108	19981222

PRIORITY APPLN. INFO.: US 1997-996308 A1 19971222
WO 1998-US27391 W 19981222

OTHER SOURCE(S): MARPAT 131:73564
GI



II

AB R1Z1ZZ2R2 [I; R1 = (un)substituted 2- or 4-pyridyl, -6-pyrimidinyl; R2 = (di)(alkyl)amino, N-containing heterocyclyl, etc.; Z = bond, O, CO,CONH, etc.; Z1 = bond, alk(en)ylene, alkynylene, etc.; Z2 = bond, alk(en)ylene, alkynylene, etc.] were prepared E.g., the dihydrochloride salt of pyridinethioethylpyrrolidine II was prepared in two steps by substitution of 2-(2-chloroethyl)-1-methylpyrrolidine with 4-pyridinethiol in DMF in the presence of potassium carbonate to give II in 49% yield as the free base, which was then converted to the hydrochloride salt. Data for biol. activity of I were given.

IT **228573-67-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation pyridine compds. as acetylcholine receptor ligands)

RN 228573-67-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(2-pyridinylthio)-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●x HCl

IT **228573-74-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation pyridine compds. as acetylcholine receptor ligands)

RN 228573-74-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(2-pyridinylthio)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:257948 CAPLUS

DOCUMENT NUMBER: 126:305665

TITLE: Synthesis of the isomers of (1R)-3-(phenylthio)tropane-2-carboxylic acid methyl ester. A new class of ligands for the dopamine transporter

AUTHOR(S): Thiruvazhi, Mohan; Abraham, Philip; Kuhar, Michael J.; Carroll, F. Ivy

CORPORATE SOURCE: Chem. Life Sci., Res. Triangle Inst., Research

Triangle Park, NC, 27709, USA
SOURCE: Chemical Communications (Cambridge) (1997), (6), 555-556
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of all four isomers of (1R)-3-(phenylthio)tropane-2-carboxylic acid Me ester are described; the 2β,3β-isomer shows high affinity for the cocaine binding site on the dopamine transporter.

IT **189264-13-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of isomers of (1R)-3-(phenylthio)tropane-2-carboxylic acid Me ester as ligands for dopamine transporter)

RN 189264-13-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **189264-11-7P 189264-12-8P 189264-14-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of isomers of (1R)-3-(phenylthio)tropane-2-carboxylic acid Me ester as ligands for dopamine transporter)

RN 189264-11-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2S,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189264-12-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189264-14-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-2-carboxylic acid, 8-methyl-3-(phenylthio)-, methyl ester, (1R,2R,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:97184 CAPLUS
DOCUMENT NUMBER: 126:104016
TITLE: Preparation of 1-hydroxyphenyl-2-hydroxypiperidinopropanols and analogs as NMDA antagonists
INVENTOR(S): Chenard, Bertrand L.; Menniti, Frank S.
PATENT ASSIGNEE(S): Pfizer Inc., USA; Chenard, Bertrand, L.; Menniti, Frank, S.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637226	A2	19961128	WO 1995-IB398	19950526
WO 9637226	A3	19961227		
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2219911	AA	19961128	CA 1995-2219911	19950526
CA 2219911	C	20040727		
EP 828513	A2	19980318	EP 1995-918111	19950526
EP 828513	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 11505828	T2	19990525	JP 1995-535520	19950526
RU 2176145	C2	20011127	RU 1996-109832	19950526
AT 258067	E	20040215	AT 1995-918111	19950526
PT 828513	T	20040531	PT 1995-918111	19950526
ES 2211904	T3	20040716	ES 1995-918111	19950526
TW 470740	B	20020101	TW 1996-85105153	19960430

IL 118328	A1	20001206	IL 1996-118328		19960520
NO 9602130	A	19961127	NO 1996-2130		19960524
AU 9654519	A1	19961205	AU 1996-54519		19960524
AU 696258	B2	19980903			
CN 1159325	A	19970917	CN 1996-107556		19960524
ZA 9604180	A	19971124	ZA 1996-4180		19960524
NZ 286656	A	20010330	NZ 1996-286656		19960524
BR 9602485	A	19980422	BR 1996-2485		19960527
CZ 283979	B6	19980715	CZ 1996-1524		19960527
US 6258827	B1	20010710	US 1997-930599		19971010
FI 9704323	A	19971125	FI 1997-4323		19971125
PRIORITY APPLN. INFO.:			HU 1996-1419	A	19960524
			CA 1995-2219911	A	19950526
			EP 1995-918111	A	19950526
			WO 1995-IB398	W	19950526

OTHER SOURCE(S): MARPAT 126:104016

GI



I



AB Title compds. [I; R1-R4 = H, halo, alkyl, alkoxy, etc.; R5 = Me or Et; R2R5 = OCH2; R6 = 4-hydroxy-4-phenylpiperidino, 3-hydroxy-3-phenylpyrrolidino, azabicycloalkyl group Q, etc.; R8 = (un)substituted Ph; Z = bond, O, S, (CH2)1-3] were prepared as NMDA antagonists (no data). Thus, 3-fluoro-4-triisopropylsilyloxy-α-bromopropiophenone (preparation given) was aminated by 4-(4-fluorophenyl)-4-hydroxypiperidine and the product reduced to give, after deprotection, title compound II.

IT **185964-15-2P 185964-53-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-hydroxyphenyl-2-hydroxypiperidinopropanols and analogs as NMDA antagonists)

RN 185964-15-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxy-3-methylphenyl)-β-methyl-, [8(αR,βR)]-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 185964-53-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxy-3,5-dimethylphenyl)-β-methyl-, [8(αR,βR)]-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **138660-51-2P 178375-07-0P 178375-08-1P**
178375-09-2P 178375-10-5P 178375-11-6P
178375-61-6P 178375-63-8P 185964-16-3P
185964-17-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-hydroxyphenyl-2-hydroxypiperidinopropanols and analogs as NMDA antagonists)
RN 138660-51-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)



RN 178375-07-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-fluorophenyl)thio]-8-methyl- (9CI) (CA INDEX NAME)



RN 178375-08-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(4-fluorophenyl)thio]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 178375-09-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-fluorophenyl)thio]- (9CI) (CA INDEX NAME)



RN 178375-10-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]-8-methyl- (9CI) (CA INDEX NAME)



RN 178375-11-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(4-chlorophenyl)thio]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 178375-61-6 CAPLUS
CN 1-Propanone, 2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-[3-methyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 178375-63-8 CAPLUS

CN 1-Propanone, 2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-[3,5-dimethyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 185964-16-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-β-methyl-α-[3-methyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-, [8(αR,βR)]-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 185964-17-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-[3,5-dimethyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-β-methyl-, [8(αR,βR)]-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:728631 CAPLUS
DOCUMENT NUMBER: 125:343047
TITLE: Phthalonitrile compound, diiminoisoindoline compound, near-IR-absorbing phthalocyanine compound and their preparation and optical information recording medium
INVENTOR(S): Tomura, Tatsuya; Sasa, Noboru; Sato, Tsutomu
PATENT ASSIGNEE(S): Ricoh Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08217737	A2	19960827	JP 1995-46286	19950210
JP 3559088	B2	20040825		
US 5863703	A	19990126	US 1996-601433	19960212
PRIORITY APPLN. INFO.:			JP 1995-46286 A	19950210
			JP 1995-47806 A	19950213

GI



I



II

AB The phthalonitrile compound and the diiminoisoindoline compound are represented by I and II (X1 = O, S; R1 = one of specified 6 cyclic substituents; n = 1, 2), resp. The phthalocyanine compound are prepared from the above compds. and suitable for CD-R.

IT **183577-21-1**
RL: DEV (Device component use); USES (Uses)
(near-IR-absorbing phthalocyanine compound for optical information recording medium)

RN 183577-21-1 CAPLUS

CN Zinc, [1,8,15,22-tetrakis[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)thio]-29H,31H-phthalocyaninato(2-)-N29,N30,N31,N32]-, (SP-4-1)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:404653 CAPLUS
DOCUMENT NUMBER: 125:86500
TITLE: Preparation of neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
INVENTOR(S): Chenard, Bertrand L.; Butler, Todd W.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606081	A1	19960229	WO 1995-IB380	19950518
W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2197451	AA	19960229	CA 1995-2197451	19950518
CA 2197451	C	20010123		

AU 9523511	A1	19960314	AU 1995-23511		19950518
AU 684359	B2	19971211			
EP 777652	A1	19970611	EP 1995-917443		19950518
EP 777652	B1	20030625			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1155279	A	19970723	CN 1995-194643		19950518
JP 09509189	T2	19970916	JP 1995-507895		19950518
JP 2888988	B2	19990510			
HU 77520	A2	19980528	HU 1997-2051		19950518
RU 2139857	C1	19991020	RU 1997-102362		19950518
CZ 290988	B6	20021113	CZ 1997-474		19950518
AT 243679	E	20030715	AT 1995-917443		19950518
PT 777652	T	20031128	PT 1995-917443		19950518
ES 2201106	T3	20040316	ES 1995-917443		19950518
IL 114892	A1	20000716	IL 1995-114892		19950810
BR 9503694	A	19960528	BR 1995-3694		19950817
ZA 9506865	A	19970217	ZA 1995-6865		19950817
US 6046213	A	20000404	US 1997-776715		19970213
FI 9700664	A	19970217	FI 1997-664		19970217
NO 9700728	A	19970217	NO 1997-728		19970217
NO 307563	B1	20000425			
PRIORITY APPLN. INFO.:			US 1994-292651	A	19940818
			WO 1995-IB380	W	19950518

OTHER SOURCE(S): MARPAT 125:86500
GI



I

AB The title compds. [I; R1-R4 = H, alkyl, halogen, CF3, OH, etc; R5 = Me, ethyl; R6 = (un)substituted piperidino, (un)substituted pyrrolidino, etc.; R2R5 = OCH2; etc.], useful for treating stroke (no data), spinal cord trauma (no data), traumatic brain injury (no data), multiinfarct dementia (no data), CNS degenerative diseases such as Alzheimer's disease (no data), etc. (no data), are prepared Thus, 3-fluoro-4-trisopropylsilyloxy-α-bromopropiophenone was reacted with 4-(4-fluorophenyl)-4-hydroxypiperidine, the intermediate reduced with NaBH4, and the free base salified with MeSO3H, producing, (1R,2R)-1-(3-fluoro-4-hydroxyphenyl)-2-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]propan-1-ol mesylate, m.p. 239-241°.

IT **138660-51-2P 178375-07-0P 178375-08-1P**
178375-09-2P 178375-10-5P 178375-11-6P
178375-61-6P 178375-62-7P 178375-63-8P
178375-64-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivs.)

RN 138660-51-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)



RN 178375-07-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-fluorophenyl)thio]-8-methyl- (9CI) (CA INDEX NAME)



RN 178375-08-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(4-fluorophenyl)thio]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 178375-09-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-fluorophenyl)thio]- (9CI) (CA INDEX NAME)



RN 178375-10-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]-8-methyl- (9CI) (CA INDEX NAME)



RN 178375-11-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(4-chlorophenyl)thio]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 178375-61-6 CAPLUS
CN 1-Propanone, 2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-[3-methyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 178375-62-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-β-methyl-α-[3-methyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 178375-63-8 CAPLUS
CN 1-Propanone, 2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-[3,5-dimethyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 178375-64-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-[3,5-dimethyl-4-[[tris(1-methylethyl)silyl]oxy]phenyl]-β-methyl- (9CI) (CA INDEX NAME)



IT **178376-00-6P 178376-01-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivs.)
RN 178376-00-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxy-3-methylphenyl)-β-methyl- (9CI) (CA INDEX NAME)



RN 178376-01-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxy-3,5-dimethylphenyl)-β-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:229078 CAPLUS
DOCUMENT NUMBER: 125:10611
TITLE: 5-(1-Hydroxy-2-piperidinopropyl)-2(1H,3H)-indolones and analogs as NMDA receptor antagonists
INVENTOR(S): Chenard, Bertrand L.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. 5,306,723.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5498610	A	19960312	US 1994-189622		19940201
US 5306723	A	19940426	US 1992-941118		19921106
PRIORITY APPLN. INFO.:			US 1992-941118	A2	19921106
			WO 1991-US1470	W	19910304

OTHER SOURCE(S): MARPAT 125:10611
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to a method of blocking N-methyl-D-aspartic (NMDA) acid receptor sites in a mammal in need thereof with an effective NMDA blocking (neuroprotective and antiischemic) amount of 5-(1-hydroxy-2-piperidinopropyl)-2(1H,3H)-indolone analogs I-III wherein A is COCRR1Yn, XC:CRYn, SO2CRR1Yn, CO-O, SO2-O (oriented from N to the ring fusion); n is 0 or 1; m is 0 or an integer from 1-6; R, R1 and R2 are each independently hydrogen or (C1-C3)alkyl; R3 and R4 are taken sep. and are each hydrogen, or R3 and R4 are taken together and are ethylene; Y is CH2 or O; Z and Z1 are independently hydrogen, (C1-C3)alkyl, (C1-C3)alkoxy, fluoro, chloro or bromo; X = H, (C1-3) alkoxy, [(C1-3)alkoxy]carbonyl; and the pharmaceutically acceptable salts thereof; methods of using these compds. in the treatment of stroke, head trauma, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised (no data). Thus, e.g., reaction of 5-(2-chloropropionyl)-2(1H,3H)-indolone with 4-hydroxy-4-benzylpiperidine afforded 34% 5-[2-(4-benzyl-4-hydroxypiperidino)propionyl]-2(1H,3H)-indolone; reduction of the latter afforded 57% 5-[2S*-(4-benzyl-4-hydroxypiperidino)-1S*-hydroxypropyl]-2(1H,3H)-indolone (IV).

IT **177186-64-0P 177186-65-1P 177186-66-2P**
177186-71-9P 177186-72-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-(1-hydroxy-2-piperidinopropyl)-2(1H,3H)-indolones and analogs as NMDA receptor antagonists)

RN 177186-64-0 CAPLUS

CN 2H-Indol-2-one, 5-[2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-hydroxypropyl]-1,3-dihydro-, [1α,3β,5α,8(1R*,2R*)]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 177186-65-1 CAPLUS
CN 2H-Indol-2-one, 5-[2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-hydroxypropyl]-1,3-dihydro-, [1α,3β,5α,8(1R*,2S*)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 177186-66-2 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[1-hydroxy-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]propyl]-, [1α,3β,5α,8(1R*,2R*)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 177186-71-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[1-hydroxy-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]propyl]-, [1α,3β,5α,8(1R*,2R*)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 177186-72-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[1-hydroxy-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]propyl]-, [1α,3β,5α,8(1R*,2S*)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **16487-39-1P 138660-42-1P 138686-09-6P 176968-78-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(5-(1-hydroxy-2-piperidinopropyl)-2(1H,3H)-indolones and analogs as NMDA receptor antagonists)
RN 16487-39-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 138660-42-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 138686-09-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-(phenylthio)-, 2,2,2-trichloroethyl ester, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 176968-78-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:448598 CAPLUS
DOCUMENT NUMBER: 117:48598
TITLE: Preparation of heterocyclic compounds as psychotropic agents
INVENTOR(S): Imuda, Junichi; Furuya, Yoshiro; Ishitoku, Takeshi; Mizuchi, Akira; Horigome, Kazutoshi; Awaya, Akira
PATENT ASSIGNEE(S): Mitsui Sekiyu Kagaku Kogyo K. K., Japan; Mitsui Seiyaku Kogyo K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04054181	A2	19920221	JP 1990-162676	19900622
JP 3036789	B2	20000424		
PRIORITY APPLN. INFO.:			JP 1990-162676	19900622
OTHER SOURCE(S):	MARPAT 117:48598			

GI



I



II



III

AB Heterocyclic compds. are prepared as serotoninergic and dopaminergic antagonists. Refluxing a mixture of pyrimidine derivative I, piperidine salt II, and K2CO2 in MeCOCH2CHMe2 gave 80% III, which showed 39% inhibition of dopamineric activity at 1 mg/mL. Also prepared and tested were 16 addnl. heterocyclic compds. Tablet, capsule, and injection formulations were given.

IT **142221-96-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as psychotropic agent)

RN 142221-96-3 CAPLUS

CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[3-[(4-fluorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]ethyl]-2,3-dihydro-7-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:83552 CAPLUS

DOCUMENT NUMBER: 116:83552

TITLE: Preparation of 5-(1-hydroxy-2-piperidinopropyl)indolones and analogs as neuroprotectants

INVENTOR(S): Chenard, Bertrand Leo

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9117156	A1	19911114	WO 1991-US1470	19910304
W: AU, BR, CA, FI, HU, JP, KR, NO, PL, RO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9174565	A1	19911127	AU 1991-74565	19910304
AU 642994	B2	19931104		
BR 9106432	A	19930504	BR 1991-6432	19910304
HU 62879	A2	19930628	HU 1992-3515	19910304
EP 554247	A1	19930811	EP 1991-905608	19910304
EP 554247	B1	20000426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506433	T2	19930922	JP 1991-505475	19910304
JP 06099423	B4	19941207		
PL 169267	B1	19960628	PL 1991-296711	19910304
RU 2068414	C1	19961027	RU 1992-16415	19910304
AT 192149	E	20000515	AT 1991-905608	19910304
ES 2146578	T3	20000816	ES 1991-905608	19910304
CA 2080475	C	20010417	CA 1991-2080475	19910304
IL 98056	A1	19951127	IL 1991-98056	19910503
ZA 9103494	A	19921230	ZA 1991-3494	19910508
CZ 280560	B6	19960214	CZ 1991-1354	19910508
SK 280833	B6	20000814	SK 1991-1354	19910508
CN 1056497	A	19911127	CN 1991-103022	19910509
CN 1037439	B	19980218		
US 5306723	A	19940426	US 1992-941118	19921106
NO 9204310	A	19921109	NO 1992-4310	19921109
NO 301979	B1	19980105		
FI 109121	B1	20020531	FI 1992-5069	19921109
FI 9802654	A	19981208	FI 1998-2654	19981208
GR 3034005	T3	20001130	GR 2000-401691	20000724
PRIORITY APPLN. INFO.:			US 1990-522332 A2	19900510
			WO 1991-US1470 A	19910304
			FI 1992-5069 A3	19921109

OTHER SOURCE(S): MARPAT 116:83552
GI



I









II

AB Title compds. [I; A = Q1-Q3, CO2, SO2O; n = 0, 1; m = 0-6; R-R2 = H, alkyl; R3, R4 = H; R3R4 = CH2CH2; X = H, alkoxy(carbonyl); Y = O, CH2; Z, Z1 = H, alkyl, alkoxy, F, Cl, Br], were prepared for treating stroke, traumatic brain injury, or CNS degenerative disease (no data). Thus, 5-(2-chloropropionyl)-2(1H,3H)-indolone, 4-hydroxy-4-benzylpiperazine, and Et3N were refluxed overnight to give a coupling product which was reduced with NaBH4 in EtOH to give title compound II.

IT **16487-39-1P 138660-42-1P 138686-09-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for neuroprotectant)

RN 16487-39-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 138660-42-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 138686-09-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-(phenylthio)-, 2,2,2-trichloroethyl ester, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **138660-25-0P 138660-26-1P 138660-35-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as neuroprotectant)
RN 138660-25-0 CAPLUS
CN 2H-Indol-2-one, 5-[2-[3-[(4-chlorophenyl)thio]-8-azabicyclo[3.2.1]oct-8-yl]-1-hydroxypropyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 138660-26-1 CAPLUS
CN 2(1H)-Quinolinone, 3,4-dihydro-6-[1-hydroxy-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 138660-35-2 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[1-hydroxy-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



IT **138660-51-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of neuroprotectant)
RN 138660-51-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chlorophenyl)thio]- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:408584 CAPLUS
DOCUMENT NUMBER: 115:8584
TITLE: Preparation of 2-piperidino-1-alkanol derivatives as antiischemic agents
INVENTOR(S): Chenard, Bertrand Leo
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 398578	A2	19901122	EP 1990-304975	19900509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
SK 279476	B6	19981104	SK 1990-2328	19890517
CZ 284342	B6	19981014	CZ 1990-2328	19900511
CA 2016860	C	19980728	CA 1990-2016860	19900515
US 5185343	A	19930209	US 1991-784446	19911023
FI 113645	B1	20040531	FI 1991-5403	19911115
US 5272160	A	19931221	US 1992-932844	19920820
US 5338754	A	19940816	US 1993-96913	19930723
US 5391742	A	19950221	US 1994-228466	19940415
US 5710168	A	19980120	US 1994-336639	19941109
US 5527912	A	19960618	US 1995-411030	19950327
PRIORITY APPLN. INFO.:			WO 1989-US2176	A 19890517
			WO 1990-US292	A 19900116
			US 1991-784446	A3 19911023
			US 1992-932844	A3 19920820
			US 1993-96913	A3 19930723
			US 1994-228466	A2 19940415
			US 1994-336639	A3 19941109

OTHER SOURCE(S): MARPAT 115:8584
GI



I



II



III

AB The title compds. (I; R = H, alkyl, alkenyl, alkynyl; X = H, OH, aryl; Y = H, OH; Y1 = aryl, aralkyl, arylthio, aryloxy, YY1 = arylmethylene, aralkylmethylene; Q = S, CH:CH), useful as antiischemic agents in treating strokes, Alzheimer's disease, Huntington's disease, and Parkinson's disease (no data), are prepared A mixture of piperidine derivative II, p-(Me2CH)3SiOC6H4COCHBrMe, and Et3N in EtOH was refluxed to give 23% propiophenone III, which was reduced with LiAlH4 to give 89% mixture of (1R*,2S*)- and (1S*,2S*)-I [R = Me, X = 4-(Me2CH)3SiO, YY1 = PhCH, Q = CH:CH] (IV). Hydrolysis of IV with Bu4N+ F- in THF at room temperature gave the mixture phenolic alc. (1S*,2S*)- and (1R*,2S*)-I (R = Me, X = 4-HO, YY1 = PhCH, Q = CH:CH). Also prepared were 75 addnl. I and intermediates.

IT **134136-73-5P 134136-85-9P 134136-86-0P 134136-87-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiischemic agent)

RN 134136-73-5 CAPLUS
CN 1-Propanone, 1-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2-[3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 134136-85-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 134136-86-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-(phenylthio)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 134136-87-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(phenylthio)- (9CI) (CA INDEX NAME)



IT **134136-97-3P 134136-98-4P 134138-54-8P**
134138-55-9P 134138-56-0P 134234-08-5P
134234-09-6P 134234-10-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiischemic agent)
RN 134136-97-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-β-methyl-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 134136-98-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-β-methyl-3-(phenylthio)- (9CI) (CA INDEX NAME)



RN 134138-54-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-β-methyl-3-(2-thienylthio)-, stereoisomer (9CI) (CA INDEX NAME)



RN 134138-55-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxyphenyl)-β-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 134138-56-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)thio]-β-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 134234-08-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-β-methyl-3-(2-thienylthio)-, stereoisomer (9CI) (CA INDEX NAME)



RN 134234-09-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-[(4-chlorophenyl)thio]-α-(4-hydroxyphenyl)-β-methyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 134234-10-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, α-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)thio]-β-methyl-, stereoisomer (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:4049 CAPLUS
DOCUMENT NUMBER: 76:4049
TITLE: Chemistry of tropan-3-yl ethers. I. Synthesis of tropan-3-yl ethers
AUTHOR(S): Kraiss, G.; Scheiber, P.; Nador, K.
CORPORATE SOURCE: Inst. Exp. Med., Hung. Acad. Sci., Budapest, Hung.
SOURCE: Journal of the Chemical Society [Section] B: Physical Organic (1971), (11), 2145-9
CODEN: JCSPAC; ISSN: 0045-6470
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Tropan-3α-yl methanesulfonate reacted, with inversion at C-3, with Na alkoxides or phenoxides to give tropan-3β-yl ethers (e.g.I). 3α-Chlorotropane, treated with Na phenoxides or benzyl oxide, gave tropan-3α-yl ethers.
IT **20400-67-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20400-67-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, bromide (9CI) (CA INDEX NAME)



● Br^-

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:90243 CAPLUS
DOCUMENT NUMBER: 72:90243
TITLE: Syntheses and the stereochemistry of tropanyl ethers
AUTHOR(S): Nador, Karoly; Kraiss, Gabor; Scheiber, Pal
CORPORATE SOURCE: Magy. Tud. Akad., Budapest, Hung.
SOURCE: Kemiai Kozlemenyek (1969), 31(4), 351-81
CODEN: KEKOAS; ISSN: 0022-9814
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
GI For diagram(s), see printed CA Issue.
AB The reaction of 3α-tropanyl methanesulfonate with NaOMe gave I (R = Me), b15 90°, n20D 1.4776; HCl salt m. 242-3°. The following I (3β-isomers) were prepared similarly (R, b.p./mm, n20D, m.p., and m.p. HCl salt given): Bu 77-8°/0.4, 1.4708, - ,

164-4.5° (p-toluenesulfonate); Ph, 103°/0.06, - , 51°, 282°; 4-ClC6H4, 117-18°/0.08, - , 60°, 284°; 2,4-Cl2-C6H3, 115°/0.25, 1.563, - , 262°; 3,4-Cl2C6H3, 115°/0.3, 1.567, - , 264°; Cl5C6, - , - , 137-8°, 264°; 4-BrC6H4, - , - , 110°, 286°; 4-IC6H4, - , - , 169-70°, 296°; 3-F3CC6H4, 99-100°/0.15, 1.498, - , 262°; 4,3-MeClC6H3, 145°/0.2, - , 83°, 273°; 3,5,-4-Me2ClC6H2, 152°/0.15, - , 98°,295°; 3-MeC6H4, 120-2°/0.1, 1.5342, - , 285°; 3,5-Me2C6H3, 133-5°/0.4, - , 86°, 284°; 3,4-Me2C6H3, 153°/0.4, - , 52°, 286°; 3,4,5-Me2C6H2, 190-5°/0.4, - , 76.5°, 301°; 4-tert-BuC6H4, 116°/0.15, 1.5312, - , 301°; 4-tert-octylphenyl, 172°/0.4, 1.528, - , 315°; 2-Ph-C6H4, - , - , 85°, 253°; 3-Me2NC6H3, 165-6°/0.3, - , 84°, 238°; 4-O2NC6H4, - , - , 106-9°, 293°; 4-H2NC6H4, - , - , - , 306°(di-HCl salt). Also prepared were Ph 3β-tropanyl thioether, b0.4 144°, n20D 1.5798(HCl salt m. 230-1°); Ph 3β-(N-isopropyl-nortropanyl) ether (HCl salt m. 220-1°), Ph 3β-(1-methyltropanyl) ether (reineckate m.159-61°), Ph 3β-(6-methoxytropanyl) ether (fumarate m. 190-1°), Ph3β-granatanyl ether (sic) (HCl salt m. 200°), and 1-methyl-4-phenoxypiperidine, b0.2 80°, n20D 1.527. The following 3α isomers of I were prepared by the method of R. Willstaetter (1903) (R, b.p./mm, n20D, m.p. and m.p. HCl salt given):Ph, 112-16°/0.3, - , 53°, 213°; 4-ClC6H4, 138-42°/0.5, - , 89-90°, 215-16°; 4-BrC6H4, - , - , 90-1°, 256°; 4-IC6H4, - , - , 107°, - ; 3-F3CC6H4, - , - , 76°, 236°; Ph-Ch2, 118-20°/0.04, 1.5355, - , 231-33°. Ph 3α-tropanyl thio ether, b0.2 125-30°, n20D 1.5812 (HCl salt m. 214-16°), was also prepared Ir and NMR spectra, dipole moments, and Kerr consts. are given and the kinetics is discussed. I (β-isomers) is antidepressant and might be used for the treatment of Parkinson's disease (L. Gyorgy, et al., 1969).

IT **16487-39-1P 16487-40-4P 16487-41-5P 16487-42-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16487-39-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 16487-40-4 CAPLUS

CN 1αH,5αH-Tropane, 3α-(phenylthio)-, hydrochloride (8CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 16487-41-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 16487-42-6 CAPLUS
CN 1αH,5αH-Tropane, 3β-(phenylthio)-, hydrochloride (8CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:487283 CAPLUS
DOCUMENT NUMBER: 69:87283
TITLE: Tropine ethers
INVENTOR(S): Nador, Karoly; Kraiss, Gabor; Gyorgy, Lajos; Pfeifer, Klara; Molnar, Jeno; Doda, Margit; Galambos, Eva
PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt.
SOURCE: Hung., 22 pp.
CODEN: HUXXAT
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 154746		19680529	HU	19660920

DE 1670463 DE
GB 1164555 GB
US 3530137 19700000 US

AB A mixture of 43.8 g. tropine methanesulfonate (I) in 300 ml. absolute MeOH and 6.9 g. Na in 200 ml. absolute MeOH was refluxed 3 hrs. to yield tropine Me ether, b17 90-3°, n20D 1.4780; hydrochloride m. 233-5° (EtOH); reineckate m. 188-199°. Tropine Bu ether, b24 138-42°, n20D 1.4708, p-toluenesulfonate m. 161.5-2° (EtOH-Et2O), reineckate m. 170-3° (Me2CO-H2O) was prepared similarly. A mixture of 36.0 g. PhONa in 250 ml. HCONMe2 and 65.7 g. I in 350 ml. HCONMe2 was refluxed 3 hrs. to yield 24.5 g. tropine Ph ether (II), b1.5 135°, n20D 1.5477, m. 50-1° (petroleum ether), hydrochloride m. 270.5-2° (decomposition) (MeOH). The following derivs. were synthesized analogously: tropine Ph thioether, b0.1 130°, n20D 1.5798; 1-methyltropine Ph ether, b10 168°, n20D 1.5362, reineckate m. 156-8° (Me2CO-H2O); N-isopropylnortropine Ph ether, b0.7 145-6°, n20D 1.5333, hydrochloride m. 214-15° (MeOH-Et2O); 6-methoxytropine Ph ether, b0.6 140-2°, n20D 1.5390, fumarate m. 185-6° (EtOH-Et2O) (the unstable 6-methoxytropine methanesulfonate could not be purified, its picrate m. 165-6° (EtOH); tropine 3-cresyl ether, b0.1 120-2°, n20D 1.5340, hydrochloride m. 275° (decomposition) (EtOH); tropine 3,5-dimethylphenyl ether, b0.4 129-34°, m. 85° (petroleum ether), hydrochloride m. 274° (decomposition); tropine 4-chlorophenyl ether, b0.08 117-18°, n20D 1.5565, m. 41-3°, hydrochloride m. 274° (decomposition); tropine 3-trifluoromethylphenyl ether, b0.15 99-100°, n20D 1.4980, hydrochloride m. 253°; tropine 2,4-dichlorophenyl ether, b0.25 155°, n20D 1.5630, hydrochloride m. 253° (EtOH-Et2O); tropine 3,4-dichlorophenyl ether, b0.3 155-6°, n20D 1.5670, hydrochloride m. 255°; tropine pentachlorophenyl ether (prepared in the absence of solvent), m. 135-6° (Me2CO), hydrochloride m. 255° (decomposition); tropine 4-chloro-3,5-dimethylphenyl ether, m. 97° (EtOH-petroleum ether), hydrochloride m. 284° (decomposition) (EtOH); tropine 3-methyl-4-chlorophenyl ether, b0.2 145°, m. 82° (petroleum ether), hydrochloride m. 263° (decomposition) (EtOH-Et2O); tropine 2-diphenylyl ether, m. 85° (EtOH-H2O), hydrochloride m. 253° (decomposition) (EtOH-Et2O); tropine 4-nitrophenyl ether, m. 105-8°, hydrochloride m. 283°; tropine 4-benzyloxyphenyl ether, m. 122°, hydrochloride m. 253° (decomposition); tropine 3,5-dichlorophenyl ether, b0.4 160°, hydrochloride m. 267° (decomposition); tropine 3,4,5-trimethylphenyl ether, m. 76°, hydrochloride m. 290° (decomposition); and tropine 4-tert-butylphenyl ether, b0.2 166°, hydrochloride m. 290° (decomposition). A solution of 1 ml. liquid MeBr in 5 ml. Me2CO was added to 2.1 g. II in 10 ml. Me2CO at -20° and the mixture heated in a sealed ampul at 80° 5 hrs. to yield N-methyl-3-phenoxytropanium bromide, m. 208° (decomposition) (Me2CO). N-Methyl-3-phenylthiotropanium bromide, m. 240° (EtOH) was obtained analogously.

IT **16487-39-1P 20400-67-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16487-39-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 20400-67-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, bromide (9CI) (CA INDEX NAME)



● Br^-

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:465956 CAPLUS
DOCUMENT NUMBER: 69:65956
TITLE: Nicotine and decamethonium-like effects of tertiary tropane-3α- and 3-β-thiophenyl ether and tropane-3β-methyl ether
AUTHOR(S): Gyorgy, Lajos; Pfeifer, A. Klara; Molnar, Jeno; Kraiss, Gabor; Nador, Karoly
CORPORATE SOURCE: Inst. Exp. Med., Hung. Acad. Sci., Budapest, Hung.
SOURCE: Acta Physiologica Academiae Scientiarum Hungaricae (1968), 33(3), 345-57
CODEN: APACAB; ISSN: 0001-6756
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tropane 3β-thiophenyl ether administered i.v. at various doses in the 0.2-2.0 mg./kg. range caused tachycardia and constricted the duodenum and nictitating membrane in cats, and antagonized dimethylphenylpiperazine in the cat duodenum and isolated guinea pig auricle. The pressor effect of tropane 3β-thiophenyl ether was biphasic, with the 1st phase antagonized by cocaine and both phases by hexamethonium. The pressor effect was rapidly abolished on repeated administration of tropane 3β-thiophenyl ether. Tropane 3α-thiophenyl ether (1-2 mg./kg.) administered i.v. to cats caused tachyphylaxis and had a biphasic pressor effect, but the 2 phases were not as distinct as with the cis isomer. Tropane 3β-methyl ether (1-2 mg./kg.) administered i.v. to cats exerted nicotine-like effects on the blood pressure and nictitating membrane. Tropane 3β-thiophenyl ether and tropane 3β-methyl ether apparently are decamethonium-like neuromuscular blocking agents, evoking fasciculation and a block which can be antagonized by tubocurarine in the cat, and inducing rectus abdominis muscle contractions in the frog.

IT **16487-39-1 16487-41-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacology of)
RN 16487-39-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 16487-41-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:427195 CAPLUS
DOCUMENT NUMBER: 69:27195
TITLE: Stereospecific methods of forming ethers by nucleophilic reactions of 3α-substituted tropanes
AUTHOR(S): Kraiss, G.; Scheiber, P.; Nador, K.
CORPORATE SOURCE: Hung. Acad. Sci., Budapest, Hung.
SOURCE: Journal of Organic Chemistry (1968), 33(6), 2601-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Stereochem. pure tropane 3β-phenyl ether (I) was obtained from 3α-(methylsulfonyloxy)tropane and NaOPh. Similarly was prepared tropane 3β-phenyl thioether (II). Similar synthesis of 3β-alkyl ether gave large amts. of trop-2-ene as the by-product. In contrast with previous findings, tropane 3α-phenyl ether was obtained from 3α-chlorotropane by treatment with NaOPh.
IT **16487-39-1P 16487-40-4P 16487-41-5P 16487-42-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16487-39-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 16487-40-4 CAPLUS

CN 1αH,5αH-Tropane, 3α-(phenylthio)-, hydrochloride (8CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 16487-41-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(phenylthio)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 16487-42-6 CAPLUS
CN 1αH,5αH-Tropane, 3β-(phenylthio)-, hydrochloride (8CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.34	280.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-16.50	-16.50

STN INTERNATIONAL LOGOFF AT 10:30:22 ON 17 FEB 2006

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox